Both Toone and Kelly have been among Wiegman's most trusted players since the Dutch coach took charge in 2020, making their ...
Target Price (Mid): ~$363Street Target: ~$279Potential Total Return: ~37%Annualized IRR: ~8% / yearWhat Happened?The FDA ...
JUVMO™ is the first and only selective D1/D5 receptor agonist approved for adults with Parkinson's disease1 Taken once daily with or without levodopa therapy, JUVMO offers patients ...
The FDA has approved Juvmo, the first and only dopamine agonist for adults with Parkinson’s disease designed to selectively ...
The US Food and Drug Administration recently approved a new drug for Parkinson's disease that works by stimulating dopamine ...
Tavapadon (Juvmo) is a new once-daily pill for Parkinson’s motor symptoms. Here’s how it works, who it may help and what to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results